Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C.
Chu TW, Kulkarni R, Gane EJ, Roberts SK, Stedman C, Angus PW, Ritchie B, Lu XY, Ipe D, Lopatin U, Germer S, Iglesias VA, Elston R, Smith PF, Shulman NS. Chu TW, et al. Among authors: ipe d. Gastroenterology. 2012 Apr;142(4):790-5. doi: 10.1053/j.gastro.2011.12.057. Epub 2012 Jan 13. Gastroenterology. 2012. PMID: 22248659 Clinical Trial.
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.
Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, Elston R, Ipe D, Morcos PN, Baher L, Najera I, Chu T, Lopatin U, Berrey MM, Bradford W, Laughlin M, Shulman NS, Smith PF. Gane EJ, et al. Among authors: ipe d. Lancet. 2010 Oct 30;376(9751):1467-75. doi: 10.1016/S0140-6736(10)61384-0. Epub 2010 Oct 14. Lancet. 2010. PMID: 20951424 Clinical Trial.
PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients.
Wedemeyer H, Jensen D, Herring R Jr, Ferenci P, Ma MM, Zeuzem S, Rodriguez-Torres M, Bzowej N, Pockros P, Vierling J, Ipe D, Munson ML, Chen YC, Najera I, Thommes J; PROPEL Investigators. Wedemeyer H, et al. Among authors: ipe d. Hepatology. 2013 Aug;58(2):524-37. doi: 10.1002/hep.26274. Epub 2013 Jun 26. Hepatology. 2013. PMID: 23348636 Clinical Trial.
Oral oseltamivir in human experimental influenza B infection.
Hayden FG, Jennings L, Robson R, Schiff G, Jackson H, Rana B, McClelland G, Ipe D, Roberts N, Ward P. Hayden FG, et al. Among authors: ipe d. Antivir Ther. 2000 Sep;5(3):205-13. Antivir Ther. 2000. PMID: 11075941 Clinical Trial.
Oral oseltamivir treatment of influenza in children.
Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, Mills RG, Ward P. Whitley RJ, et al. Among authors: ipe d. Pediatr Infect Dis J. 2001 Feb;20(2):127-33. doi: 10.1097/00006454-200102000-00002. Pediatr Infect Dis J. 2001. PMID: 11224828 Clinical Trial.
A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators.
Kobashigawa J, Miller L, Renlund D, Mentzer R, Alderman E, Bourge R, Costanzo M, Eisen H, Dureau G, Ratkovec R, Hummel M, Ipe D, Johnson J, Keogh A, Mamelok R, Mancini D, Smart F, Valantine H. Kobashigawa J, et al. Among authors: ipe d. Transplantation. 1998 Aug 27;66(4):507-15. doi: 10.1097/00007890-199808270-00016. Transplantation. 1998. PMID: 9734496 Clinical Trial.
41 results